2357 GMT - A2 Milk's more than 30% share-price fall since April began looks too steep to UBS, despite unanswered questions following China supply shortages and a U.S. product recall. UBS upgrades A2 Milk to buy, from neutral, while lowering its price target by 12% to NZ$9.20/share. Analyst Marcus Curley says the share-price drop outpaces what UBS considers to be a 12% permanent loss of value. UBS believes the likelihood of further infant formula product recalls is low. "FY26 earnings risk has moderated with China infant-formula restocking underway," UBS says. "We expect net profit to double by FY30 driven by infant formula share gains from new products across both English-label and China label plus margin expansion from internalised manufacturing." A2 Milk is up 0.3% at NZ$7.50. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 18, 2026 19:57 ET (23:57 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.